Back to News
Market Impact: 0.45
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
Source: PR Newswire
Healthcare & Biotech
The Phase 3 G-HOPE-001 study of arcotatug tavatecan met both primary endpoints, reporting statistically significant and clinically meaningful overall-survival and progression-free-survival benefits in previously treated patients with CLDN18.2-positive gastric cancer. The excerpt provides no effect sizes, p-values, or additional trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
- Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall